MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
- Conditions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT04535557
Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04454918
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04121078
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04091438
- Locations
- 🇺🇸
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇯🇵SOUSEIKAI PS Clinic, Hakata-ku, Fukuoka-Ken, Japan
🇺🇸Pulmonary Associates Clinical Trials, Glendale, Arizona, United States
Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04091425
- Locations
- 🇺🇸
Pulmonary Associates Clinical Trials, Glendale, Arizona, United States
🇺🇸Wright Clinical Research, Alabaster, Alabama, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04056455
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04056468
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Hialeah, Florida, United States
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04051827
- Locations
- 🇦🇺
Peninsula and Southeast Oncology, Frankston, Victoria, Australia
🇸🇬Raffles Hospital, Singapore, Singapore
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03990649
- Locations
- 🇬🇧
Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, England, United Kingdom
🇬🇧St Pancras Clinical Research, London, England, United Kingdom
A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03928327
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States